528 related articles for article (PubMed ID: 31058910)
1. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
3. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
5. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
6. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
10.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
11.
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
[No Abstract] [Full Text] [Related]
12. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Diagnosis and Management:
Sanli Y; Garg I; Kandathil A; Kendi T; Zanetti MJB; Kuyumcu S; Subramaniam RM
AJR Am J Roentgenol; 2018 Aug; 211(2):267-277. PubMed ID: 29975116
[TBL] [Abstract][Full Text] [Related]
14.
Tremblay S; Beaudoin JF; Bélissant Benesty O; Ait-Mohand S; Dumulon-Perreault V; Rousseau É; Turcotte ÉE; Guérin B
J Nucl Med; 2023 Feb; 64(2):232-238. PubMed ID: 35906092
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
17. Radiosynthesis of clinical doses of ⁶⁸Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based ⁶⁸Ge/⁶⁸Ga generators.
Tworowska I; Ranganathan D; Thamake S; Delpassand E; Mojtahedi A; Schultz MK; Zhernosekov K; Marx S
Nucl Med Biol; 2016 Jan; 43(1):19-26. PubMed ID: 26702783
[TBL] [Abstract][Full Text] [Related]
18. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
19. Long-Acting Somatostatin Analog Therapy Differentially Alters
Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM
J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
[TBL] [Abstract][Full Text] [Related]
20. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]